DOCSLIB.ORG

Study Protocol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Study Protocol Protocol HVTN 505 Phase 2b, randomized, placebo-controlled test-of- concept trial to evaluate the safety and efficacy of a multiclade HIV-1 DNA plasmid vaccine followed by a multiclade HIV-1 recombinant adenoviral vector vaccine in HIV-uninfected, adenovirus type 5 neutralizing antibody negative, circumcised men and male-to-female (MTF) transgender persons, who have sex with men DAIDS Document ID 10753 BB IND 13971 held by DAIDS Clinical trial sponsored by Division of AIDS (DAIDS) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Department of Health and Human Services (DHHS) Bethesda, Maryland, USA Vaccine provided by Dale and Betty Bumpers Vaccine Research Center (VRC), NIAID, NIH Bethesda, Maryland, USA July 21, 2014 HVTN 505, Version 6.0 HVTN 505, Version 6.0 / July 21, 2014 At the first planned interim analysis for efficacy futility, conducted under Version 4 of the protocol on April 22, 2013, the DSMB recommended that the trial be stopped for efficacy futility. A total of 71 HIV infections had been diagnosed in the MITT cohort (41 among vaccine recipients, 30 among placebo recipients). Of these, 48 constituted primary endpoints (Week 28+ HIV infections diagnosed on or after Day 196 post-enrollment); 27 occurred among vaccine recipients and 21 among placebo recipients. There was no statistically significant difference in the rate of HIV infection between treatment arms, either in the Week 28+ cohort (estimated hazard ratio = 1.25; 95% CI: 0.71 to 2.20; p = 0.446) or in the MITT cohort (hazard ratio = 1.33; 95% CI: 0.83 to 2.13; p = 0.230). However, given that the number of HIV infections was larger in the vaccine arm, and given that there was a trend toward the hazard ratio increasing over time since enrollment (p = 0.09), the DSMB recommended, and the study team agreed, to continue to follow all participants beyond the Month 24 visit (the terminal visit in Version 4 of the protocol). Under Version 5 of the protocol, participants were followed post-unblinding to 48 months post-enrollment. Additional interim analyses were conducted at six-month intervals to evaluate the HIV-1 acquisition rate in the two treatment arms, and to evaluate conditional power to detect an increased rate of acquisition in the vaccine arm as compared to the placebo arm. At the second interim analysis, conducted on March 24, 2014 under Version 5 of the protocol, the study oversight group recommended that the protocol be revised to reduce the frequency of post-unblinding follow-up visits. A total of 109 HIV infections had been diagnosed in the MITT cohort to 48 months post-enrollment (53 among vaccine recipients and 56 among placebo recipients). There was no statistically significant difference in the rate of HIV-1 infection between treatment arms, either including all follow-up to 48 months post-enrollment (estimated hazard ratio = 0.92; 95% CI: 0.63 to 1.34; p = 0.65), or restricting follow-up to 24 months post- enrollment (estimated hazard ratio = 1.09; 95% CI: 0.72 to 1.66; p = 0.68). Given these data, there was very low power (< 1%) to detect an increased rate of HIV-1 infection in the vaccine vs. placebo arm, if the study were to continue following participants as specified under Version 5 of the protocol. As described in Sections 8.2 and 8.2.1, under Version 6 of the protocol participants will continue to be followed to 48 months post- enrollment, with an additional health contact at 60 months, but with study visits only annually following Month 24. The goal of this extended follow-up is to continue to monitor the rate of HIV-1 acquisition in the two treatment arms. To this end, the rate of study dropout will also continue to be evaluated in each treatment arm. The objectives of the study have been modified accordingly. Assessing the rates of study dropout and of HIV infection in the vaccine vs. placebo arms are now the primary objectives (see Section 5.2). Assessing the impact of vaccination on post-infection endpoints and on immunogenicity; assessing modification of vaccine effects by host immune genetic and other factors; and assessing immune correlates of risk are now exploratory objectives (see Section 5.4). HVTN505_v6.0_FINAL.docx / Page 2 of 112 HVTN 505, Version 6.0 / July 21, 2014 Contents 1 Ethical considerations .............................................................................................. 5 2 IRB/IEC review considerations ............................................................................... 7 2.1 Risks to participants ...................................................................................... 7 2.2 Risk/benefit balance ...................................................................................... 7 2.3 Subject selection ............................................................................................ 8 2.4 Informed consent ........................................................................................... 9 2.5 Safety monitoring .......................................................................................... 9 2.6 Privacy/confidentiality .................................................................................. 9 3 Overview ................................................................................................................ 11 3.1 Protocol Team ............................................................................................. 14 4 Background and rationale ...................................................................................... 15 4.1 HIV epidemic and epidemiology ................................................................. 15 4.2 Ad5 nAb assays ........................................................................................... 28 4.3 Study vaccines ............................................................................................. 28 4.4 Non-clinical and natural history data that provide evidence of potential vaccine activity ............................................................................................ 31 4.5 Potential benefit of VL reduction as a vaccination outcome ....................... 34 4.6 Experience with the VRC vaccine regimen ................................................. 37 5 Objectives and endpoints of the unblinded extended follow-up phase .................. 48 5.1 Primary objective and endpoints ................................................................. 48 5.2 Exploratory objectives ................................................................................. 48 6 Statistical considerations ........................................................................................ 50 6.1 Overview ..................................................................................................... 50 6.2 Objectives .................................................................................................... 50 6.3 Endpoints ..................................................................................................... 51 6.4 Sample size rationale ................................................................................... 52 6.5 Sampling design for assessing prophylactic ARV use ................................ 52 6.6 Statistical analysis ....................................................................................... 52 6.7 Monitoring of trial ....................................................................................... 55 7 Selection and withdrawal of participants ............................................................... 56 7.1 Inclusion criteria .......................................................................................... 56 7.2 Exclusion criteria ......................................................................................... 57 7.3 Co-enrollment of HVTN 505 participants ................................................... 58 7.4 Participant termination from the study ........................................................ 59 8 Clinical procedures ................................................................................................ 60 8.1 Informed consent ......................................................................................... 60 8.2 Follow-up visits for HIV-uninfected participants ....................................... 61 8.3 Procedures for HIV-1–infected participants ................................................ 62 8.4 HIV risk reduction counseling ..................................................................... 63 8.5 Visit windows and missed visits .................................................................. 64 8.6 Early termination visit ................................................................................. 64 9 HIV-1 infection assessment and clinical response ................................................. 65 9.1 HIV-1 symptom assessment ........................................................................ 65 9.2 HIV-1 testing during post-unblinding follow-up ......................................... 65 9.3 Endpoint adjudication .................................................................................. 65 9.4 HIV-1 infection during the study................................................................. 66 HVTN505_v6.0_FINAL.docx / Page 3 of 112 HVTN 505, Version 6.0 / July 21, 2014 9.5 Medical care for participants who become HIV-1–infected ........................ 66 10 Laboratory .............................................................................................................
Load more

Recommended publications
  • The CAB Bulletin HIV Vaccines and the Community
    The CAB Bulletin HIV Vaccines and the Community Planning for PrEP My First Time By Genevieve Meyer, HVTN Community Education Unit By Dino Martino, On November 23rd, 2010, the results of the iPrEx study were released. The Orlando, FL CAB member. 2,499-person study demonstrated that a daily dose of oral Truvada®, (a With nervous excitement I accepted combination of two antiretroviral medications, emtricitabine and tenofovir) could the offer to attend my first HVTN reduce new infections of HIV in gay men, transwomen and other men who have conference. As a member of the sex with men (MSM) by an average of 43.8%. The HVTN salutes the sponsors, newly formed CAB in Orlando, this study team, and volunteers in the 11 sites throughout Brazil, Ecuador, Peru, South Africa, Thailand and the United States who contributed to this study’s success. was another “first time” opportu- nity in a series of events that I have The results of the iPrEx study have added increased vigor to the HVTN’s search had the pleasure to be a part of in for a safe and effective HIV vaccine. One central question being asked at the HVTN support of the work of the HVTN. right now is what these results mean for participants in HVTN 505, a study which is also enrolling MSM and transwomen who are at risk of contracting HIV. As a pharmacist for nearly two de- cades, scientific conferences are not The Network has set up a working group to solicit feedback from community new to me; still, each one brings stakeholders about possible changes to HVTN 505 based on the iPrEx results.
    [Show full text]
  • T. Franklin Williams Scholars Program
    Developing a New Generation of Medical Subspecialists with Expertise in Aging and Care of the Elderly T. Franklin Williams Scholars Program Report to T. Franklin Williams Scholars Program Evaluation Team ASP Geriatrics Steering Committee Integrating Geriatrics Project Evaluation Team May 2011 Submitted by: Erika D. Tarver Project Administrator Association of Specialty Professors 330 John Carlyle Road Suite 610 Alexandria, VA 22314 T: (703) 341-4540 F: (703) 519-1890 [email protected] Kevin P. High, MD Principal Investigator William R. Hazzard, MD Co-Principal Investigator Table of Contents Narrative Progress Report Application and Award Progress Summary of Success of T. Williams Scholars Program Appendices A. 2008 Scholars 24-Month Progress Reports Neena S. Abraham, MD (Note: This is Dr. Abraham’s final report) Steven G. Coca, DO Jeffrey G. Horowitz, MD Danelle F. James, MD Heidi Klepin, MD George C. Wang, MD 2009 Williams Scholars Progress Reports and Summary of 18-Month Questionnaire B. Peter Abadir, MD 12-month Progress Report C. Kathleen M. Akgun, MD 12-Month Progress Report Publication D. Alison Huang, MD 12-Month Progress Report Publication E. Eswar Krishnan, MD 12-Month Progress Report Publication F. Rohit Loomba, MD Publication G. Sharmilee Nyenhuis, MD 12-Month Progress Report Publication H. Peter P. Reese, MD 12-Month Progress Report Publication I. Erik B. Schelbert, MD 12-Month Progress Report Publication J. Helen Keipp Talbot, MD 12-Month Progress Report Publication K. Summary of 18-Month Questionnaire 2010 Williams Scholars Mentor Interviews and Summary of Six-Month Questionnaire L. Kellie Hunter-Campbell, MD Six-Month Mentor Interview M.
    [Show full text]
  • Antibody Fc Effector Functions and Igg3 Associate with Decreased HIV-1 Risk
    RESEARCH ARTICLE The Journal of Clinical Investigation Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk Scott D. Neidich,1 Youyi Fong,2,3,4 Shuying S. Li,2,3 Daniel E. Geraghty,5 Brian D. Williamson,4 William Chad Young,2 Derrick Goodman,1 Kelly E. Seaton,1 Xiaoying Shen,1 Sheetal Sawant,1 Lu Zhang,1 Allan C. deCamp,2 Bryan S. Blette,6 Mengshu Shao,2 Nicole L. Yates,1 Frederick Feely,1 Chul-Woo Pyo,3 Guido Ferrari,1,7,8 HVTN 505 Team,9 Ian Frank,10 Shelly T. Karuna,3 Edith M. Swann,11 John R. Mascola,12 Barney S. Graham,12 Scott M. Hammer,13 Magdalena E. Sobieszczyk,13 Lawrence Corey,3 Holly E. Janes,2,3,4 M. Juliana McElrath,3 Raphael Gottardo,2,3 Peter B. Gilbert,2,3,4 and Georgia D. Tomaras1,7,8,14 1Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA. 2Statistical Center for HIV/AIDS Research and Prevention, 3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4Department of Biostatistics, University of Washington, Seattle, Washington, USA. 5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 6Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA. 7Department of Surgery and 8Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA. 9The HVTN 505 Team is detailed in the Supplemental Acknowledgments. 10Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia Pennsylvania, USA. 11Division of AIDS and 12Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. Jaworski PII: S2319-4170(20)30209-2 DOI: https://doi.org/10.1016/j.bj.2020.11.011 Reference: BJ 374 To appear in: Biomedical Journal Received Date: 2 September 2020 Revised Date: 6 November 2020 Accepted Date: 22 November 2020 Please cite this article as: Jaworski JP, Neutralizing monoclonal antibodies for COVID-19 treatment and prevention, Biomedical Journal, https://doi.org/10.1016/j.bj.2020.11.011. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Chang Gung University. Publishing services by Elsevier B.V. TITLE: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. JAWORSKI Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina KEYWORDS: SARS-CoV-2, Coronavirus, Monoclonal Antibody, mAb, Prophylaxis, Treatment CORRESPONDING AUTHOR: Dr. Juan Pablo Jaworski, DVM, MSc, PhD. Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria Las Cabañas y de los Reseros (S/N), Hurlingham (1686), Buenos Aires, Argentina Tel / Fax: 054-11-4621-1447 (int:3400) [email protected] ABSTRACT The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
    [Show full text]
  • HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects
    Working Paper No.6 HIV/AIDS Technologies: A review of progress to date and current prospects COMMISSIONED BY: aids2031 Science and Technology Working Group AUTHORED BY: KEITH ALCORN NAM Publications Disclaimer: The views expressed in this paper are those of the author(s) and do not necessarily reflect the official policy, position, or opinions of the wider aids2031 initiative or partner organizations aids2031 Science and Technology working group A review of progress to date and current prospects October 2008 Acronyms 3TC lamivudine ANRS Agènce Nationale de Récherche sur la Sida ART Antiretroviral therapy ARV Antiretroviral AZT azidothymidine or zidovudine bDNA branched DNA CDC US Centers for Disease Control CHER Children with HIV Early Antiretroviral therapy (study) CTL Cytotoxic T-lymphocyte D4T stavudine DSMB Data and Safety Monitoring Board EFV Efavirenz ELISA Enzyme Linked Immunosorbent Assay FDC Fixed-dose combination FTC Emtricitabine HAART Highly Active Antiretroviral Therapy HBAC Home-based AIDS care HCV Hepatitis C virus HPTN HIV Prevention Trials Network HSV-2 Herpes simplex virus type 2 IAVI International AIDS Vaccine Initiative IL-2 Interleukin-2 LED Light-emitting diode LPV/r Lopinavir/ritonavir MIRA Methods for Improving Reproductive Health in Africa trial MSF Médecins sans Frontières MSM Men who have sex with men MVA Modified vaccinia Ankara NIH US National Institutes of Health NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBT Optimised background therapy PCR Polymerase
    [Show full text]
  • Safety and Immunogenicity of a Recombinant Adenovirus Serotype
    C S & lini ID ca A l f R o e l s Fuchs et al., J AIDS Clin Res 2015, 6:5 a e n a r r u c o h J AIDS & Clinical http://dx.doi.org/10.4172/2155-6113.1000461 ISSN: 2155-6113 Research Research Article Open Access Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals Jonathan D Fuchs1,2,*, Pierre-Alexandre Bart3, Nicole Frahm4, Cecilia Morgan4, Peter B Gilbert4, Nidhi Kochar4, Stephen C DeRosa4, Georgia D Tomaras5, Theresa M Wagner1, Lindsey R Baden6, Beryl A Koblin7, Nadine G Rouphael8, Spyros A Kalams9, Michael C Keefer10, Paul A Goepfert11, Magdalena E Sobieszczyk12, Kenneth H Mayer13, Edith Swann14, Hua-Xin Liao5, Barton F Haynes5, Barney S Graham15 and M Juliana McElrath4 for the NIAID HIV Vaccine Trials Network 1Population Health Division, San Francisco Department of Public Health, San Francisco, CA, USA 2Department of Medicine, University of California, San Francisco, San Francisco, USA 3Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 5Human Vaccine Institute, Duke University, Durham, NC, USA 6Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USA 7Laboratory of Infectious Disease Prevention, New York Blood Center, New York, NY, USA 8The Hope Clinic, Division of Infectious Diseases, Emory University, Atlanta, GA, USA 9Infectious Diseases Division, Vanderbilt University School of Medicine, Nashville,
    [Show full text]
  • (Sexpro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States
    Title: Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. Authors Title Email Site Hyman Scott [email protected] Bridge HIV, San Francisco Department of (corresponding) Public Health, San Francisco, California Eric Vittinghoff [email protected] University of California, San Francisco, San Francisco, CA Risha Irvin [email protected] John’s Hopkins School of Medicine, Baltimore, Maryland Albert Liu [email protected] Bridge HIV, San Francisco Department of Public Health, San Francisco, CA LaRon Nelson [email protected] University of Rochester. Rochester, New er.edu York Carlos Del Rio [email protected] Emory University, Atlanta, Georgia Manya Magnus [email protected] George Washington University, Washington, District of Columbia Sharon [email protected] Columbia University, New York, New Mannheimer York Sheldon Fields [email protected] Charles Drew School of Medicine, Los Angeles, California Irene Kuo [email protected] George Washington University, Washington, District of Columbia Steve Shoptow [email protected] University of California, Los Angeles, California Beatrice [email protected] Instituto de Pesquisa Clinica Evandro Grinsztejn Chagas (IPEC), Rio de Janeiro, Brazil Jorge Sanchez [email protected] Asociacion Civil Impacta Salud y Educacion, Lima, Peru Steven [email protected] Fred Hutchinson Cancer Research Center, Wakefield Seattle, Washington Jonathan Fuchs [email protected]
    [Show full text]
  • Advancing Toward HIV-1 Vaccine Efficacy Through the Intersections of Immune Correlates
    Vaccines 2014, 2, 15-35; doi:10.3390/vaccines2010015 OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Review Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates Georgia D. Tomaras 1,* and Barton F. Haynes 2 1. Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke Human Vaccine Institute, Durham, NC 27710, USA 2. Departments of Medicine and Immunology, Duke Human Vaccine Institute, Durham, NC 27710, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-919-681-5598; Fax: +1-919-684-5230. Received: 29 October 2013; in revised form: 29 October 2013 / Accepted: 9 December 2013 / Published: 27 December 2013 Abstract: Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine clinical trials have provided hypotheses regarding the mechanisms of induction of protective immunity to HIV-1. To date, there have been six HIV-1 vaccine efficacy trials (VAX003, Vaxgen, Inc., San Francisco, CA, USA), VAX004 (Vaxgen, Inc.), HIV-1 Vaccine Trials Network (HVTN) 502 (Step), HVTN 503 (Phambili), RV144 (sponsored by the U.S. Military HIV Research Program, MHRP) and HVTN 505). Cellular, humoral, host genetic and virus sieve analyses of these human clinical trials each can provide information that may point to potentially protective mechanisms for vaccine-induced immunity. Critical to staying on the path toward development of an efficacious vaccine is utilizing information from previous human and non-human primate studies in concert with new discoveries of basic HIV-1 host-virus interactions. One way that past discoveries from correlate analyses can lead to novel inventions or new pathways toward vaccine efficacy is to examine the intersections where different components of the correlate analyses overlap (e.g., virus sieve analysis combined with humoral correlates) that can point to mechanistic hypotheses.
    [Show full text]
  • The CAB Bulletin HIV Vaccines and the Community in This Issue: S
    The CAB Bulletin HIV Vaccines and the Community In this Issue: S. Africa CAB Retreat 2 CROI, GCAB Elections 3 Full Group Meeting 4-5 Honors & Awards 6-7 Calls & Announcements 8 From Unique Paths, Hope Takes Action— The Community Education Unit Reflections on the U.S./Swiss CAB Retreat Welcomes Niles Eaton By Reese Aaron Isbell, San Francisco CAB member Those who attended the Full Group Editor’s note on the CAB Retreats: From April 9-11, 2010 the CEU conducted a Meeting were introduced to the new U.S./Swiss CAB Retreat in Seattle, Washington. It was similar in format to the manager of the HVTN Community South African CAB retreat (see article by Siyabonga Nzimande in this issue): a Education Unit (CEU), Niles Eaton. train-the-trainer approach where CAB members worked with staff from the CEU to Niles may be new to the CEU but he present on topics such as an Introduction to Vaccinology, Introduction to Research is certainly not new to community Ethics, How to Read a Protocol, Vaccine-Induced Seropositivity, and many more. education or to the HVTN. Niles has Originally scheduled for June, 2010, the Latin American and Caribbean CAB spent the last seven years as a Clinical Retreat will take place in late Trials Manager and is incredibly 2010 or early 2011. “We all had two important knowledgeable about site operations We arrived separately and things in common: we were and structures. we ranged in age, race, Prior to joining creed and color. We were volunteers, and we were the HVTN, Niles gay, bi, straight, single, part of a world-wide effort to spent seven married (legally and eradicate HIV/AIDS.” years as a study one-day-soon-to-be).
    [Show full text]
  • HVTN CAB Bulletin HIV Vaccines and the Community
    HVTN CAB Bulletin HIV Vaccines and the Community In this Issue: Cape Town CAB Member Gets Published 2 HVAD Around the World 3 HVTN Conference Highlights 4 Welcome Jim Maynard! The Global CAB Welcomes David The Community Galetta as New Co-Chair Education Unit By Carrie Schonwald, Community Education Unit welcomed Jim Maynard as the new Associate Director We would like to announce the election of for Community Reverend David Galetta as International Development GCAB Co-Chair. David is currently the and Recruitment CAB Chairperson of the Desmond Tutu (overseeing both HIV Foundation in Cape Town, South Jim Maynard, Associ- ate Director for Com- Community Education Africa, where he has been a CAB member munity Development and Communications) since 2004. Rev. Galetta graduated with a & Recruitment. on May 16. Prior to the Post Graduate Diploma in International HVTN, Jim spent over Research Ethics from the University of Cape David Galetta, new international GCAB 12 years at the Fenway Institute (part Town in 2009 and serves on their Human Co-Chair. of Fenway Health) where he served as Sciences Research Ethics Committee as the Associate Director for Community …continues on page 7 Engagement. Jim brings a wealth of knowledge and experience gained during his years working with HVTN trials HVTN 505 Expands in Size and Scope as well as the HIV Prevention Trials Network (HPTN), the Microbicide Trials By Rick Church, Rich Trevino, Coco Alinsug, Jason Roberts (Community Network (MTN) and the Adolescent Trials members of the HVTN 505 protocol team) and Gail Broder, HVTN Community Network (ATN). His team leadership, Education Unit site perspective, depth of experience, and relentlessly positive energy will be a welcome addition the Core team.
    [Show full text]
  • HIV?AIDS Researchers at the NIH Clinical Center
    The NIH Clinical Center treats a diverse group of patients from all over the world. It also draws researchers from different cultures and backgrounds. Learn more about some of the many researchers who conduct their work on the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the Clinical Center. Thomas C. Quinn, M.D., M.Sc., conducts research for the National Institute of Allergy and Infectious Diseases at the NIH Clinical Center. He is a senior investigator and chief of the International HIV/STD Section of the Laboratory of Immunoregulation. Dr. Quinn obtained his M.D. from Northwestern University. He was a research associate in infectious diseases in the NIAID Laboratory of Parasitic Diseases and completed a fellowship in infectious diseases at the University of Washington. Since 1981, he has been assigned to the division of infectious diseases at Johns Hopkins University, where he became a professor of medicine in 1991. Dr. Quinn is a member of the Institute of Medicine and the National Academy of Sciences and is a fellow of the American Association for the Advancement of Science. His major areas of research are: Definition of epidemiologic features of HIV-1 and HIV-2 infections in developing countries and the United States Assessment of biomedical interventions to control HIV, including circumcision, prevention of mother-to-child transmission, pre-exposure prophylaxis, and vaccine development Assessment of the frequency of Chlamydia trachomatis infections in selected populations using noninvasive sensitive nucleic-acid amplification assays for diagnosis Evaluations of interventions to control blinding trachoma due to Chlamydia trachomatis in sub-Saharan Africa See the full program description.
    [Show full text]
  • That Record-Breaking Sprint to Create a COVID-19 Vaccine The
    NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 29 ISSUE 5 • SEPTEMBER-OCTOBER 2021 That Record-breaking The Intersection of Man and Machine Sprint to Create a Bionics Gives New Hope to Those Living With Physical Disabilities COVID-19 Vaccine BY MICHAEL TABASKO, OD BY MELISSA GLIM At the end of 2019, most people were looking forward to an exciting 2020, a new decade starting with those magic numbers, 20-20, that denote a sharpness of vision. There would be the Summer Olympics in Japan and the U.S. presidential election. Meanwhile, intramural scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) were designing vaccines for several coronaviruses using a promising, new platform based on messenger RNA (mRNA). Everything changed on a Saturday morning in early January. Chinese scientists CREDIT: TH0MAS BULEA (LEFT); NIH CLINCAL CENTER (RICHT) had isolated a new coronavirus that was (Left) The NIH pediatric exoskeleton for children with cerebral palsy and other movement disorders uses custom actuators causing a serious epidemic in China’s Wuhan from Agilik developed as part of a cooperative research and development agreement with NIH, along with embedded sensors and microcontrollers, to provide overground gait training while worn. (Right) Alexander Theodorakos, a participant province and released its genetic sequence to in a research protocol at the NIH Clinical Center that is evaluating the new pediatric exoskeleton, and Thomas Bulea, the the scientific community around the world. study’s principal investigator, discuss how the device changes the way the legs move when walking. Barney Graham, director of the VRC’s Viral Pathogenesis Laboratory (VPL), and If popular culture is any indication, the notion that bionic technology will VRC research fellow Kizzmekia Corbett someday redefine the boundaries of human function has long held our collective dropped everything and began using this fascination.
    [Show full text]